Switch theme
Sign up to access all valuation multiples
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue.
2010
11K+
LTM Revenue $4.2B
LTM EBITDA -$225M
$26.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BeiGene has a last 12-month revenue of $4.2B and a last 12-month EBITDA of -$225M.
In the most recent fiscal year, BeiGene achieved revenue of $490M and an EBITDA of -$51.0M.
BeiGene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BeiGene valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $316M | $490M | XXX | XXX | XXX |
| Gross Profit | $145M | $267M | XXX | XXX | XXX |
| Gross Margin | 46% | 55% | XXX | XXX | XXX |
| EBITDA | -$144M | -$51.0M | XXX | XXX | XXX |
| EBITDA Margin | -46% | -10% | XXX | XXX | XXX |
| Net Profit | -$258M | -$113M | XXX | XXX | XXX |
| Net Margin | -81% | -23% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BeiGene's stock price is HKD 158 (or $20).
BeiGene has current market cap of HKD 221B (or $28.4B), and EV of HKD 209B (or $26.9B).
See BeiGene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.9B | $28.4B | XXX | XXX | XXX | XXX | $-0.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BeiGene has market cap of $28.4B and EV of $26.9B.
BeiGene's trades at 6.4x LTM EV/Revenue multiple, and -119.6x LTM EBITDA.
Analysts estimate BeiGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BeiGene and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $26.9B | XXX | XXX | XXX |
| EV/Revenue | 54.8x | XXX | XXX | XXX |
| EV/EBITDA | -526.8x | XXX | XXX | XXX |
| P/E | -342.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -311.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBeiGene's NTM/LTM revenue growth is 29%
BeiGene's revenue per employee for the last fiscal year averaged $45K, while opex per employee averaged $44K for the same period.
Over next 12 months, BeiGene's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BeiGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BeiGene and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 55% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -65% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 18% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $45K | XXX | XXX | XXX | XXX |
| Opex per Employee | $44K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 51% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 99% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BeiGene acquired XXX companies to date.
Last acquisition by BeiGene was XXXXXXXX, XXXXX XXXXX XXXXXX . BeiGene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BeiGene founded? | BeiGene was founded in 2010. |
| Where is BeiGene headquartered? | BeiGene is headquartered in Hong Kong. |
| How many employees does BeiGene have? | As of today, BeiGene has 11K+ employees. |
| Who is the CEO of BeiGene? | BeiGene's CEO is Mr. John V. Oyler. |
| Is BeiGene publicy listed? | Yes, BeiGene is a public company listed on HKG. |
| What is the stock symbol of BeiGene? | BeiGene trades under 06160 ticker. |
| When did BeiGene go public? | BeiGene went public in 2018. |
| Who are competitors of BeiGene? | Similar companies to BeiGene include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BeiGene? | BeiGene's current market cap is $28.4B |
| What is the current revenue of BeiGene? | BeiGene's last 12-month revenue is $4.2B. |
| What is the current EBITDA of BeiGene? | BeiGene's last 12-month EBITDA is -$225M. |
| What is the current EV/Revenue multiple of BeiGene? | Current revenue multiple of BeiGene is 6.4x. |
| What is the current EV/EBITDA multiple of BeiGene? | Current EBITDA multiple of BeiGene is -119.6x. |
| What is the current revenue growth of BeiGene? | BeiGene revenue growth between 2023 and 2024 was 55%. |
| Is BeiGene profitable? | Yes, BeiGene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
